openPR Logo
Press release

Novel Drug Delivery Systems to Augment Presbyopia Therapeutics Pipeline

07-17-2019 02:44 PM CET | Health & Medicine

Press release from: Pharma Proff

Novel Drug Delivery Systems to Augment Presbyopia Therapeutics

Presbyopia is a common vision disorder that manifests with increasing age. With age, the ciliary muscles of the eye start losing their flexibility that leads to the eye lens losing its flexibility as well. The eye gradually loses its ability to focus light directly on to the retina, and the image ends up forming behind it. This results in poor visibility of objects that are close to the eye. The normal aging process that causes presbyopia cannot be stopped or reversed. However, it can be rectified by wearing contact lenses and eyeglasses, or via surgeries.

Download the report sample at: https://www.pharmaproff.com/request-sample/1233

Signs and symptoms associated with presbyopia are a difficulty in reading small prints, headaches, eye muscle fatigue, and eyestrain. One of its early signs is blurred vision while holding things at the normal reading distance. Working in dimly lit environments could exacerbate the condition. Its diagnosis is done based on the patient’s age and medical history. In case of premature presbyopia, medical history becomes more important as it may correlate with a systemic disease. Conditions, such as neurological and vascular diseases, trauma, and diabetes mellitus and certain drugs, may lead to premature presbyopia.

The treatment for presbyopia is based on ophthalmologists and optometrists’ recommendations. The initial treatment involves prescribing of near-vision optical aids, such as reading glasses, magnifying lenses, and monocles. Vison-correction surgeries are also used for the treatment for long-sightedness (another term for the condition), as is the experimental pharmaceutical approach. One of the investigational drugs in the presbyopia therapeutics pipeline is naphazoline. Other drugs, such as polyethylene glycol, pheniramine, and nepafenac, are being tried with alpha-1 agonists, as they reduce ciliary muscle spasm, vascular congestion, and pilocarpine-induced hyperemia, thereby treating excess pupil constriction.

Get the detailed analysis at: https://www.pharmaproff.com/report/presbyopia-therapeutics-pipeline-analysis

One of the key driving factors for the presbyopia therapeutics pipeline is the invention of novel drug delivery systems. For example, AcrySof IQ PanOptix Toric intraocular lens for presbyopia was launched by the eye care division of Novartis, which is seen as a significant development in the presbyopia treatment scene. This is indicated for adults who have undergone cataract surgery and wish to achieve independence from spectacles. Similarly, the U.S. Food and Drug Administration approved the Raindrop Near Vision Inlay to be implanted in the cornea for presbyopia correction, in 2016.

The presbyopia therapeutics pipeline is segmented by development phase, route of administration, and molecule type. One of the candidates in the pipeline is carbachol and brimonidine drops, being developed by Principal Investigator Almamoun Abdelkader of the Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo. Carbachol is a positively charged quaternary ammonium compound and a synthetic choline ester. The effect of acetylcholine on nicotinic and muscarinic receptors is mimicked by carbachol, which is a parasympathomimetic compound. The intraocular pressure is ultimately reduced due to the induction of miosis in the eye.

Brimonidine is a selective alpha-2 adrenergic receptor agonist and an imidazole derivative. It binds to these receptors present on the presynaptic nerve endings of the dilator muscle, which inhibits the neurotransmitter release into the synaptic cleft. This reduces the activity of the dilator muscle, thereby leading to a more-mitotic pupil. The production of aqueous humor is decreased due to the action of this compound on blood vessels, which causes them to constrict.

Therefore, as more such combination therapies are devised, people suffering from presbyopia might not have such a hard time in the coming years.

Contact Us:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novel Drug Delivery Systems to Augment Presbyopia Therapeutics Pipeline here

News-ID: 1806123 • Views: 203

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Presbyopia

Global Presbyopia Correction Devices Market 2019 - AcuFocus, Refocus, Presbia
This new report by Eon Market Research, titled “Global Presbyopia Correction Devices Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Presbyopia Correction Devices industry at a global as well as regional and country level. Key facts analyzed in this report include the Presbyopia Correction Devices market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses
Presbyopia Market Growth And Restrain Factors Analysis H1 2017
Overview Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.  Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555348-presbyopia-pipeline-review-h1-2017 Report Highlights The Presbyopia (Ophthalmology) pipeline guide also reviews of key players
Presbyopia Therapeutics Pipeline Analysis 2018
Presbyopia Pipeline Analysis The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a
Presbyopia - Pipeline Review, H2 2017 - MarketResearchReports.
"The Report Presbyopia - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H2 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens
Presbyopia - Pipeline Review, H1 2017
Report Hive Market Research Released a New Research Report of 30 pages on Title " Presbyopia - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies. Presbyopia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly
Asia-Pacific Presbyopia Correction Device Market Report 2017
MarketResearchReports.Biz presents this most up-to-date research on "Asia-Pacific Presbyopia Correction Device Market Report 2017" Description In this report, the Asia-Pacific Presbyopia Correction Device market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share